Sa1477: ROLE OF INTRAVENOUS IMMUNOGLOBULIN IN TREATMENT OF DRUG REFRACTORY GASTROPARESIS

Chhabra, Garvit; Mathur, Prateek; McElmurray, Lindsay; Moppins, Carmelita; Nguyen, Vincent; Rogers, Benjamin D.; Pinkston, Christina; Abell, Thomas L.; Stocker, Abigail

doi:10.1016/s0016-5085(22)60925-9

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Modalities like parenteral immunoglobulin infusions have produced symptomatic improvement in these patients when used alone or in conjunction with other modalities, such as gastric electrical stimulation and pyloroplasty. 16,21 The results of responders and nonresponders to IVIG in one study are detailed in ►Fig. 2.…”

Section: Systemic Antibodies In Gastroparesis Syndromesmentioning

confidence: 99%

Gastroparesis and Gastroparesis Syndromes as Neuromuscular Disorders

Naing,

Mathur,

Chhabra

et al. 2023

Semin Neurol

Self Cite

View full text Add to dashboard Cite

Gastroparesis syndromes (GpS) are a spectrum of disorders presenting with characteristic symptoms increasingly recognized as being gastrointestinal (GI) neuromuscular disorders (NMDs). This review focuses on GpS as a manifestation of neurologic disorders of GI NMD. GpS can be associated with systemic abnormalities, including inflammatory, metabolic, and serologic disorders, as well as autoimmune antibodies via nerve and muscle targets in the GI tract, which can be treated with immunotherapy, such as intravenous immunoglobulin. GpS are associated with autonomic (ANS) and enteric (ENS) dysfunction. Disorders of ANS may interact with the ENS and are the subject of continued investigation. ENS disorders have been recognized for a century but have only recently begun to be fully quantified. Anatomic structural changes in the GI tract are increasingly recognized in GpS. Detailed descriptions of anatomic changes in GpS, and their correlation with physiologic findings, have opened a new era of investigation. The management of GpS, when viewed as GI NMD, has shifted the paradigms of both diagnosis and treatment. This article concludes with current approaches to GpS directed at underlying neuromuscular pathology.

show abstract

Section: Systemic Antibodies In Gastroparesis Syndromesmentioning

confidence: 99%